Research
Hormonal
GLP-1 RA users had higher rates of cardiovascular complications (RR = 1.426, p = 0.038).
Practitioners should monitor cardiovascular health in patients using GLP-1 RAs.
StrongQualifiesmedium confidence
However, GLP-1 RA users had higher rates of cardiovascular complications (RR = 1.426, p = 0.038).
Why this rating
Based on a retrospective cohort study design.
Source
Outcomes of primary rotator cuff repair in non-diabetic patients using glucagon-like peptide-1 (GLP-1) receptor agonists: A propensity-matched analysis
J Ambrose Martino et al. · Shoulder & Elbow · 2026
DOI 10.1177/17585732261434004
cohort
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →